Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3
December 27th, 2010
13.3K views
HIV tropism can be inferred from the V3 region of the viral envelope. V3 is PCR amplified in triplicate using nested RT-PCR, sequenced, and interpreted using bioinformatic software. Samples with with 1 or more sequence(s) with low g2P scores are classified as non-R5 virus.
Overview
This study outlines a method for inferring HIV tropism by sequencing the V3 region of the viral envelope gene. The approach utilizes nested RT-PCR and bioinformatics to classify the virus as R5 or non-R5 based on sequence analysis.
Key Study Components
Area of Science
- Virology
- Molecular Biology
- Infectious Diseases
Background
- HIV tropism is crucial for determining treatment options.
- The V3 region of the HIV envelope is key for co-receptor usage.
- Traditional methods for tropism testing can be costly and time-consuming.
- This study presents a more efficient alternative using sequencing techniques.
Purpose of Study
- To develop a cost-effective method for determining HIV tropism.
- To utilize nested RT-PCR for amplifying the V3 region.
- To analyze sequences for co-receptor usage classification.
Methods Used
- Extraction of HIV RNA from patient plasma.
- Nested RT-PCR amplification of the V3 region.
- Gel electrophoresis to confirm amplification success.
- Sequencing of amplified products and bioinformatic analysis.
Main Results
- Successful amplification of the V3 region in triplicate.
- Identification of viral tropism as R5 or non-R5 based on sequence analysis.
- Demonstration of the method's efficiency compared to traditional assays.
- Potential for broader application in clinical settings.
Conclusions
- The developed method provides a reliable means of inferring HIV tropism.
- This approach can be implemented in various laboratory settings.
- It offers a faster and more economical alternative to existing methods.
Frequently Asked Questions
What is HIV tropism?
HIV tropism refers to the specific co-receptors that HIV uses to enter host cells, which is critical for treatment decisions.
Why is the V3 region important?
The V3 region of the HIV envelope is key for determining the virus's co-receptor usage, influencing its infectivity and treatment response.
What is nested RT-PCR?
Nested RT-PCR is a sensitive technique that amplifies specific RNA sequences, allowing for the detection of low-abundance viral RNA.
How does this method compare to traditional tropism testing?
This method is more cost-effective and faster than traditional phenotypic assays, making it accessible for more laboratories.
What are the implications of determining HIV tropism?
Determining HIV tropism helps in selecting appropriate antiretroviral therapies, particularly those targeting CCR5 co-receptors.
Executive Industry Relevance
Accurate HIV tropism assessment is essential for patient stratification prior to CCR5-antagonist therapy, directly impacting treatment efficacy and safety. Population-based V3 sequencing enables rapid, cost-effective genotypic inference of co-receptor usage, supporting timely go/no-go decisions in antiviral development. This method reduces reliance on phenotypic assays, expanding accessibility for preclinical and clinical virology laboratories.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables mechanistic de-risking by confirming CCR5-dependent viral entry phenotypes in preclinical models.
- Operational Value: Supports target validation through genotypic confirmation of tropism, reducing false positives in antagonist screening.
Screening & Assay Development
- Scientific Value: Generates quantitative sequence data amenable to standardized bioinformatic analysis (e.g., geno2pheno) for reproducible tropism classification.
- Operational Value: Facilitates assay standardization via triplicate nested RT-PCR and population-based sequencing, improving inter-laboratory concordance.
Translational & Preclinical Research
- Scientific Value: Provides disease-relevant tropism data from patient-derived samples, enhancing predictive confidence in antiviral efficacy.
- Operational Value: Enables longitudinal monitoring of viral evolution and tropism shift during preclinical studies.
Pipeline & Workflow Integration
The method fits within the antiviral discovery continuum from target validation through lead optimization, providing tropism data that informs compound selection and mechanistic de-risking.
- Discovery Biology: Supports hypothesis testing of CCR5 as a therapeutic target by confirming viral dependence on this co-receptor.
- Screening: Delivers quantitative, sequence-based outputs that enable reliable compound evaluation against CCR5-using strains.
- Analytics: Generates geno2pheno false positive rate (FPR) metrics, with <5.75% FPR indicating non-R5 tropism, supporting objective decision thresholds.
- Translational Research: Connects genotypic tropism to clinical response prediction, aligning with biomarker-guided antiviral development.
- Enterprise Reuse: Establishes a reusable genotyping platform for antiviral programs requiring co-receptor stratification.
Operational & Enterprise Impact
- Scientific Value: Improves predictive confidence in target engagement by distinguishing R5 and non-R5 viral populations.
- Operational Value: Reduces time and cost versus phenotypic assays, requiring only standard sequencing infrastructure.
- Strategic Value: Increases capital efficiency by enabling early exclusion of non-responders in CCR5-antagonist programs.
- Portfolio Impact: Supports risk-adjusted prioritization of compounds based on patient tropism profiles.
Implementation Considerations
- Requires expertise in molecular virology, nested RT-PCR, and bioinformatic sequence analysis.
- Dependent on access to thermal cyclers, electrophoresis systems, and Sanger or NGS sequencing platforms.
- Necessitates standardized protocols for triplicate amplification and consensus calling to ensure reproducibility.
- Must account for mixed viral populations and potential sequencing artifacts in diverse clinical samples.
- Limited to genotypic inference; phenotypic confirmation may be needed for discordant or complex samples.
Biopharma FAQs
Why does geno2pheno false positive rate below 5.75% indicate non-R5 tropism?
A geno2pheno false positive rate (FPR) below 5.75% is the established threshold for predicting non-R5 HIV tropism, indicating reduced likelihood of response to CCR5-antagonist therapy. This cutoff is derived from clinical data optimizing sensitivity and specificity for co-receptor inference.
How does triplicate nested RT-PCR improve reliability of V3 region amplification?
Performing nested RT-PCR in triplicate increases sampling depth of the viral quasispecies, enhancing detection of minority non-R5 variants that may be missed in single reactions. This approach reduces false-negative tropism calls due to stochastic amplification failure.
What quantitative output enables tropism classification from V3 sequences?
The geno2pheno algorithm generates a false positive rate (FPR) score from V3 amino acid sequences, which quantitatively predicts co-receptor usage. An FPR <5.75% classifies the virus as non-R5, guiding CCR5-antagonist suitability.
Why are replication requirements critical for cross-functional tropism testing?
Replicate amplification and sequencing ensure that tropism calls are not driven by PCR or sequencing errors, increasing confidence in results shared between virology, clinical, and translational teams. Consistency across replicates supports reliable data transfer in multicenter studies.
What statistical analysis is required before implementing population-based V3 sequencing for tropism?
Implementation requires validation of the geno2pheno FPR threshold (<5.75%) against phenotypic tropism assays in the target population, establishing analytical sensitivity and specificity. Laboratories must also define acceptable limits for sequence quality and replicate concordance.
